4//SEC Filing
Welsh Amy 4
Accession 0001104659-24-092943
CIK 0001261249other
Filed
Aug 25, 8:00 PM ET
Accepted
Aug 26, 5:39 PM ET
Size
7.4 KB
Accession
0001104659-24-092943
Insider Transaction Report
Form 4
Welsh Amy
Chief Commercial Officer
Transactions
- Disposition to Issuer
Common Stock
2024-08-26$1.52/sh−3,375$5,130→ 0 total - Disposition to Issuer
Common Stock
2024-08-26$1.52/sh−10,125$15,390→ 3,375 total
Footnotes (2)
- [F1]Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 10,125 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $15,390, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person.
- [F2]Upon the consummation of the Merger, pursuant to the Merger Agreement, 3,375 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $5,130, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person.
Documents
Issuer
AGILE THERAPEUTICS INC
CIK 0001261249
Entity typeother
Related Parties
1- filerCIK 0001951262
Filing Metadata
- Form type
- 4
- Filed
- Aug 25, 8:00 PM ET
- Accepted
- Aug 26, 5:39 PM ET
- Size
- 7.4 KB